Please login to the form below
IPO
This page shows the latest IPO news and features for those working in and with pharma, biotech and healthcare.
Newly-listed BioNTech buys Neon to boost cell therapy assets
share the company secured for shares in its IPO less than two years ago.
Latest news
-
Sanofi said to be looking at options for $30bn consumer health unit
IPO), according to the sources.
-
France’s Innate Pharma eyes $100m Nasdaq IPO
The remainder of the potential IPO funding will go towards projects that, for now at least, lie outside the AZ alliance. ... Citi, SVB Leerink, and Evercore ISI are the joint bookrunners for the IPO.
-
Medimmune-born Viela files $150m IPO, eyes first product launch
The money raised in the IPO will give the Maryland-based biotech the financial muscle it needs to start building the commercial platform for its lead drug inebilizumab, which has just ... rivals. The $150m IPO adds to a $75m second-round fundraising that
-
Mega-mergers dominate as buoyant markets lift biopharma
The biggest biotech flotation in the first six months was the $348.5 IPO in June by BridgeBio, the San Francisco biotech focused on genetic diseases.
-
BioNTech raises €290m for mRNA cancer vaccine platform
Meanwhile, Denmark's Genmab is gearing up for an IPO in the US next week, in which it is expected to raise $503m, which will consolidate its status as one of
More from news
Approximately 3 fully matching, plus 97 partially matching documents found.
Latest Intelligence
-
Building European biotech firms to rival those of the US
in order to raise major capital via an initial public offering (IPO).
-
European biotech: a new generation of leaders emerges
In April last year, it achieved a very successful IPO on the US Nasdaq, generating $208m thanks to investor belief in its cancer-focused antibody-based pipeline. ... healthcare company and the second largest US IPO ever by a biotech company.
-
Is China ready for a pharmaceutical gold rush?
The first company to list, Ascletis Pharma Inc, was valued at $2bn when its IPO closed on 1 August.
-
Chinese biotech’s global ambitions
It launched an IPO in the US two years ago, but now its public offering in China has helped swell its coffers enormously – which will help fuel its big ambitions.
-
Biopharma's Future: Made in China
scale.”. Having just raised a gargantuan $903m via an IPO on the newly deregulated Hong Kong exchange, the company is bullish about becoming one of those Chinese-headquartered global pharma companies, ... Tencent’s WeDoctor, which produces diagnosis
More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.
Latest appointments
-
Christie Anbar appointed global healthcare lead at Ruder Finn
In those roles, she led award-winning work for a range of client from pre-IPO startups to emerging biotech, large pharma and medical device companies, as well as patient and
-
Novimmune appoints Guillaume de Sampaïo
During that time he contributed to the development of the company's clinical trial portfolio and the facilitation of its successful US IPO during 2014.
-
Kite Pharma names Cynthia Butitta as CFO
Her other previous roles include chief financial officer and chief operating officer of Telik where she was responsible for securing over $450m through an initial public offering (IPO).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- World AIDS Day 35: Medscape’s Commitment to the Elimination of HIV through Education and Looking Towards the Future
- No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards
- Building trust with HCPs: 6 takeaways from our industry webinar
- Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m
- NHS to offer stem cell transplants to patients living with rare blood disorder
- First WHO Global Clinical Trial Forum develops joint vision to improve clinical research
No results were found
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
